Volume 8: Issue 3

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD, Chair, SLC, University of Michigan Health System Ann Arbor, Michigan
David B. Badesch, MD, SLC Immediate Past-Chair, University of Colorado Health Sciences Center, Aurora, Colorado
John H. Newman, MD, SLC Vice-Chair, Vanderbilt Medical School, Nashville, Tennessee
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania
Todd Bull, MD, University of Colorado Health Sciences Center, Denver, Colorado
Richard Channick, MD, Editor-in Chief, Advances in Pulmonary Hypertension

Summaries and commentaries from the section editors present a clinical context for practitioners' application of recently published research relevant to care of patients with pulmonary hypertension.

AP Chua, MD

Download as Powerpoint
Download Figure

OA Minai, MD

Download as Powerpoint
Download Figure

Introduction

Cor pulmonale has a well-described association with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and interstitial lung diseases.1 This association is felt to be the result of chronic hypoxic pulmonary vasoconstriction as well as a complex interaction of molecular pathways culminating in pulmonary vascular remodeling. The WHO clinical classification of pulmonary hypertension (PH) includes these patients in WHO Class III (PH associated with lung diseases and/or hypoxemia), which also incorporates patients with sleep disordered breathing.2 Obstructive sleep apnea

Global experts in pulmonary hypertension attended the 2009 American College of Chest Physicians meeting in San Diego. While there, Dr Nicholas Hill, Chief of the Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, and Professor of Medicine, Tufts University, Boston; and Dr Steven Nathan, Medical Director, Lung Transplant and Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, Virginia, talked with guest editor Dr Omar A. Minai to share their perspectives on current diagnosis, management, and future outlook for pulmonary hypertension patients with existing lung disease and hypoxia.

The Clinical Trials Update was created as a way to highlight new and ongoing research trials that are evaluating therapies for pulmonary arterial hypertension (PAH). In this issue we highlight 2 multicenter trials that recently led to FDA approval for 2 new PAH therapies: PHIRST-1 and TRIUMPH-1.

Translating Evidence into Clinical Practice

Editor's Memo

The Scientific Leadership Council of the Pulmonary Hypertension Association

Emmanuel Weitzenblum, MD, Pioneer in Right Heart Catheterization

Ask the Expert

Are there any data indicating that medication such as bosentan or Revatio^™ (sildenafil citrate) or any other medication helps secondary pulmonary hypertension for a patient with mitral regurgitation, obstructive sleep apnea, and pulmonary artery systolic pressure of 85 mm Hg?

Article Reviews

Pulmonary Hypertension in Obstructive Sleep Apnea Syndrome

Introduction

Diagnosis and Management of Pulmonary Hypertension Associated With Pulmonary Fibrosis

Pulmonary Hypertension Associated With Sarcoidosis

Case Vignette

Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Diagnosis and Management

PH in Patients with Lung Disease and Hypoxia

Clinical Trials Update

PHRN Corner

Choosing a Home Oxygen System

Conference Abstracts

Guest Editor’s Memo

A Roundtable Discussion Addressing Patient-Centered Care and Quality of Life in Patients With Pulmonary Arterial Hypertension

Editor’s Memo

Pulmonary Hypertension Associated With Parenchymal Lung Disease